,Keyword_1,frequency,Keyword_2,degreee
0,liquid biopsy,77,liquid biopsy,219
1,circulating tumor cells,20,circulating tumor cells,51
2,circulating tumor dna,10,exosomes,37
3,exosomes,10,ctdna,32
4,ctdna,9,circulating tumor dna,27
5,lung cancer,9,lung cancer,26
6,nsclc,7,cancer,26
7,cancer,7,nsclc,21
8,cell-free dna,6,cell-free dna,19
9,liquid biopsies,5,egfr,16
10,egfr,5,biomarkers,16
11,biomarkers,5,liquid,14
12,non-small cell lung cancer,4,liquid biopsies,13
13,circulating tumor cell,4,circulating tumor cell,13
14,liquid,4,early detection,13
15,breast cancer,4,breast cancer,13
16,t790m,3,non-small cell lung cancer,11
17,early detection,3,ctcs,11
18,extracellular vesicles,3,cell free dna,10
19,exosome,3,exosome,9
20,cell free dna,3,mutation,8
21,circulating tumor dna (ctdna),2,t790m,8
22,egfr mutation,2,screening,8
23,ctc,2,extracellular vesicles,8
24,biomarker,2,cfdna,8
25,cancer screening,2,biomarker,7
26,minimal residual disease,2,microrna,7
27,mutation,2,cerebrospinal fluid,7
28,progression,2,circulating tumor cell (ctc),7
29,microrna,2,mirna,7
30,next generation sequencing,2,precision medicine,6
31,circulating tumour cells (ctcs),2,circulating free dna,6
32,cerebrospinal fluid,2,molecular profile,6
33,personalized medicine,2,driver mutations,6
34,screening,2,ctrna,6
35,epidermal growth factor receptor,2,tumor-educated platelets,6
36,circulating,2,mutations,6
37,next-generation sequencing,2,gene,6
38,precision medicine,2,egfr mutations,6
39,circulating free dna,2,circulating tumor dna (ctdna),5
40,molecular profile,2,ctc,5
41,driver mutations,2,cancer screening,5
42,circulating tumor cell (ctc),2,minimal residual disease,5
43,ctcs,2,progression,5
44,circulating tumor cells (ctcs),2,personalized medicine,5
45,mirna,2,sclc transformation,5
46,cfdna,2,1790m,5
47,egfr mutations,2,ddpcr,5
48,pancreas cancer,1,circulating,5
49,plasma dna tissue mapping,1,peptide nucleic acid,5
50,epigenome,1,biosensors,5
51,copy number,1,dna,5
52,plasma genotyping,1,next-generation sequencing,5
53,pleural effusion,1,minimal residual,5
54,pulmonary adenocarcinoma,1,egfr mutation,4
55,extracellular,1,colorectal carcinoma,4
56,microfluidics,1,prognostic,4
57,solid-phase amplification,1,predictive,4
58,risk stratification,1,alk,4
59,prostate,1,ros1,4
60,colorectal carcinoma,1,resistance,4
61,prognostic,1,next generation sequencing,4
62,predictive,1,liquid biosources,4
63,egfr testing,1,diagnostic,4
64,sclc,1,circulating tumour cells (ctcs),4
65,cdx,1,central nervous system,4
66,monitoring,1,cns,4
67,alk,1,csf,4
68,ros1,1,circulating dna,4
69,resistance,1,epidermal growth factor receptor,4
70,pcr,1,t790m mutation,4
71,early disease detection,1,cobas ver2,4
72,monitoring of egfr tki treatment,1,pna-lna pcr clamp,4
73,egfr t790m mutation,1,her2,4
74,dynamic monitoring,1,personalized therapy,4
75,alk mutation,1,oncolbx,4
76,hepatocellular carcinoma,1,cfrna,4
77,bladder cancer,1,urine,4
78,advanced nsclc,1,markers,4
79,egfr/t790m,1,extracellular rna,4
80,digital droplet pcr,1,cancer biomarkers,4
81,outcomes,1,exrna,4
82,histopathology,1,dna methylation,4
83,urooncology,1,ncrna,4
84,personalizing therapy,1,epigenetic marker,4
85,liquid biosources,1,plasma tumor dna,4
86,diagnostic,1,brain tumor,4
87,uterine aspirate,1,plasma dna tissue mapping,3
88,central nervous system,1,epigenome,3
89,cns,1,copy number,3
90,csf,1,plasma genotyping,3
91,germline mutation,1,pleural effusion,3
92,hereditary cancer,1,pulmonary adenocarcinoma,3
93,urological cancer,1,extracellular,3
94,colon cancer,1,microfluidics,3
95,gene mutation,1,solid-phase amplification,3
96,genomic evolution,1,risk stratification,3
97,re-biopsy,1,prostate,3
98,oral cancer,1,pcr,3
99,circulating tumour dna,1,advanced nsclc,3
100,single cell analysis,1,egfr/t790m,3
101,deep-sequencing,1,digital droplet pcr,3
102,tumor marker,1,outcomes,3
103,cancer diagnostics,1,histopathology,3
104,egfr t790 m-positive nsclc,1,urooncology,3
105,osimertinib,1,personalizing therapy,3
106,circulating dna,1,germline mutation,3
107,tumor biomarkers,1,hereditary cancer,3
108,clinical trials,1,colon cancer,3
109,peptide nucleic acid-locked,1,gene mutation,3
110,primary brain tumor,1,genomic evolution,3
111,glioma,1,re-biopsy,3
112,bronchoalveolar lavage fluid,1,single cell analysis,3
113,prognosis,1,deep-sequencing,3
114,treatment responses,1,tumor marker,3
115,cell-free nucleic acid,1,cancer diagnostics,3
116,t790m mutation,1,egfr t790 m-positive nsclc,3
117,cobas ver2,1,osimertinib,3
118,pna-lna pcr clamp,1,clinical trials,3
119,sclc transformation,1,primary brain tumor,3
120,1790m,1,glioma,3
121,ddpcr,1,prognosis,3
122,genetic,1,treatment responses,3
123,cell-free ctdna,1,cell-free nucleic acid,3
124,ovarian cancer,1,genetic,3
125,circulating cell-free dna,1,cell-free ctdna,3
126,peptide nucleic acid,1,ovarian cancer,3
127,biosensors,1,circulating cell-free dna,3
128,dna,1,liquid biopsy diagnostics,3
129,nanosheet,1,molecular markers,3
130,long,1,metastasis,3
131,pulmonary fibrosis,1,cell free tumor dna,3
132,cell-free dna (cfdna),1,clinical application,3
133,nipple aspirate fluid,1,afatinib,3
134,liquid biopsy diagnostics,1,digital pcr,3
135,molecular markers,1,prospective study,3
136,metastasis,1,droplet pcr,3
137,cell free tumor dna,1,next generation,3
138,clinical application,1,lung adenocarcinoma,3
139,her2,1,cancer surveillance,3
140,personalized therapy,1,genomics,3
141,oncolbx,1,translational medical research,3
142,afatinib,1,circulating tumor cells (ctcs),3
143,digital pcr,1,exosomal isolation,3
144,prospective study,1,nsclc biomarker,3
145,molecular diagnostics,1,intra-tumor heterogeneity,3
146,immunotherapy liquid biopsy,1,disease,3
147,pd-l1 circulating tumor cells,1,targeted therapy,3
148,droplet pcr,1,eml4-alk,3
149,next generation,1,rt-qpcr,3
150,lung adenocarcinoma,1,mirna analysis,3
151,epidermal growth factor receptor (egfr),1,curative treatment,3
152,non-small cell,1,tumor,3
153,cfrna,1,circulating biomarker,3
154,liquid-based endometrial cytology,1,epigenetics,3
155,intrauterine sampling,1,pancreas cancer,2
156,surepath (tm),1,egfr testing,2
157,cancer surveillance,1,sclc,2
158,genomics,1,cdx,2
159,ctrna,1,monitoring,2
160,tumor-educated platelets,1,early disease detection,2
161,mutations,1,monitoring of egfr tki treatment,2
162,gene,1,egfr t790m mutation,2
163,urine,1,dynamic monitoring,2
164,markers,1,alk mutation,2
165,free circulating dna,1,hepatocellular carcinoma,2
166,extracellular rna,1,bladder cancer,2
167,cancer biomarkers,1,uterine aspirate,2
168,exrna,1,urological cancer,2
169,translational medical research,1,oral cancer,2
170,next-generation sequencing (ngs),1,circulating tumour dna,2
171,non-small cell lung cancer (nsclc),1,tumor biomarkers,2
172,exosomal isolation,1,peptide nucleic acid-locked,2
173,nsclc biomarker,1,bronchoalveolar lavage fluid,2
174,dna methylation,1,pulmonary fibrosis,2
175,ncrna,1,cell-free dna (cfdna),2
176,epigenetic marker,1,nipple aspirate fluid,2
177,plasma tumor dna,1,molecular diagnostics,2
178,metastatic breast,1,immunotherapy liquid biopsy,2
179,brain tumor,1,pd-l1 circulating tumor cells,2
180,minimal residual,1,epidermal growth factor receptor (egfr),2
181,intra-tumor heterogeneity,1,non-small cell,2
182,disease,1,liquid-based endometrial cytology,2
183,targeted therapy,1,intrauterine sampling,2
184,breast liquid biopsy cancer,1,surepath (tm),2
185,eml4-alk,1,free circulating dna,2
186,rt-qpcr,1,metastatic breast,2
187,mirna analysis,1,alk rearranged lung cancer,2
188,curative treatment,1,circulating tumor-derived dna,2
189,alk rearranged lung cancer,1,egf receptor,2
190,circulating tumor-derived dna,1,brush biopsy,2
191,egf receptor,1,liquid-based cytology,2
192,tumor,1,slide-based cytology,2
193,circulating biomarker,1,nanosheet,1
194,epigenetics,1,long,1
195,brush biopsy,1,next-generation sequencing (ngs),1
196,liquid-based cytology,1,non-small cell lung cancer (nsclc),1
197,slide-based cytology,1,breast liquid biopsy cancer,1
